Let's Stop HIV Together - Part 2: Pharmacology Update: Ceftriaxone and Cabotegravir

  • April 14, 2021


Let's Stop HIV Together - Part 2: Pharmacology Update: Ceftriaxone and Cabotegravir


  • Casey Messer, PA-C (LinkedIn)
  • Jonathan Baker, PA-C (LinkedIn)
  • Diane Bruessow, MPAS, PA-C, DFAAPA (LinkedIn)
  • Sam Wijesinghe, DHSc, MS, MPAS, PA-C, AAHIVS (LinkedIn)

Duration: 1 hour

Date: Wednesday, April 14, 8:30 pm EDT / 5:30 pm PDT

At the conclusion of this session, participants should be able to:

  1. Understand the use of injectable cabotegravir/rilpivirine for treatment of HIV
  2. Analyze safety and efficacy data from clinical trials of cabotegravir for HIV prevention
  3. Reference updated CDC guidelines for the treatment of gonorrhea across varying anatomical sites and patient populations
  4. Reference clinician resources from CDC 


While HIV treatment and prevention has evolved significantly over the past 4 decades, over 35,000 HIV infections occur annually in the US. New data, guidelines, and recommendations provide opportunities for progress toward ending the HIV epidemic. Cabotegravir/rilpivirine is the first and only, complete, long-acting injectable treatment for HIV. Cabotegravir is also a candidate  to receive an indication for use as  HIV preexposure prophylaxis (PrEP) following reported data from 2 major clinical trials. STIs can facilitate HIV transmission; therefore, screening for, diagnosis of, and appropriate treatment of bacterial STIs including gonorrhea is essential in the care of people living with and at risk for HIV. Recently, the CDC released new guidelines on the treatment of gonorrhea to recommend an increased, single dose, ceftriaxone-based regimen.

Register Here: https://lbgtpa.wildapricot.org/event-4205440

APAOG Member Discount Code: ENDHIV21

Powered by Wild Apricot Membership Software